Antibody drug conjugate (ADC)

Antibody-drug conjugate
#Antibody drug conjugate (ADC) #Drug discovery #Webinar

Webinar: Learn how to streamline ADC discovery

Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar, available on-demand, will demonstrate how integrated strategies help overcome these hurdles and support informed preclinical decisions. Innovative chemistry enables efficient conjugation, optimised linkers,… Read More

Webinar date:
Supported by BioDuro
#News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Drug discovery #Webinar

Webinar: Overcome the hurdles in ADC discovery

Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar, available on-demand, will demonstrate how integrated strategies help overcome these hurdles and support informed preclinical decisions. Innovative chemistry enables efficient conjugation, optimised linkers,… Read More

Webinar date:
Supported by BioDuro
#News

Antibody-drug conjugates
#Antibody drug conjugate (ADC) #Drug discovery #Webinar

Webinar: Practical insights on accelerating ADC discovery

Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar, available on-demand, will demonstrate how integrated strategies help overcome these hurdles and support informed preclinical decisions. Innovative chemistry enables efficient conjugation, optimised linkers,… Read More

Webinar date:
Supported by BioDuro
#News

Antibody-drug conjugates
#Antibody drug conjugate (ADC) #Drug discovery #Webinar

Accelerating ADC discovery through strategically integrated chemistry, biology, and DMPK

Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar demonstrates how integrated strategies help overcome these hurdles and support informed preclinical decisions. Innovative chemistry enables efficient conjugation, optimised linkers, and payload selection,… Read More

Webinar date:
Supported by BioDuro
#Webinars

#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Last chance to register: Understand LC-MS quantification strategies for proteins

A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar, taking place on 27 March, will… Read More

Webinar date:
Supported by Evotec
#News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Biotherapeutics #Drug discovery #eBook

eBook: A smarter path to ADC quality – fractionate, analyse, decide

A new eBook is now available to download from Bio-Techne entitled ‘Advances in the analysis of next-generation biotherapeutics’. Discover how to accelerate ADC development with clearer, faster characterisation of charge heterogeneity and size/purity. This eBook explains when to apply advanced icIEF and CE-SDS methods for ADCs and other novel biotherapeutics… Read More

#News

#Antibody drug conjugate (ADC) #Biotherapeutics #Drug discovery #eBook

Advances in the analysis of next-generation biotherapeutics

Discover how to accelerate ADC development with clearer, faster characterisation of charge heterogeneity and size/purity. This eBook explains when to apply advanced icIEF and CE-SDS methods for ADCs and other novel biotherapeutics to accelerate development timelines. Learn: icIEF vs IEX for ADC charge profiles Protecting unstable ADCs with on-board mixing… Read More

#eBooks #Resources

#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Webinar: Learn about LC-MS-based bioanalytical approaches

A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar, taking place on 27 March, will… Read More

Webinar date:
Supported by Evotec
#News

Cancer research in laboratory
#Antibody drug conjugate (ADC) #Biotech #Breast cancer

VALANX raises €3m to advance breast cancer ADC programme 

Biotech company VALANX Biotech has raised €3 million to advance its lead antibody-drug conjugate (ADC) programme to treat metastatic triple-negative breast cancer.  The company will use the financing for the pre-clinical development of VLX-ADC-001, a LIV-1-targeting ADC for metastatic triple-negative breast cancer (mTNBC), with candidate selection planned for June 2026.  ADCs are a… Read More

#Business & Investment #News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Register now to understand advanced LC-MS bioanalytical strategies for biologics

A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar, taking place on 27 March, will… Read More

Webinar date:
Supported by Evotec
#News

Monoclonal antibodies
#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Webinar: Quantitative analysis of therapeutic proteins

A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar, taking place on 27 March, will… Read More

Webinar date:
Supported by Evotec
#News

Biologic drugs
#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Webinar: Explore cutting-edge LC-MS-based bioanalytical approaches

A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar, taking place on 27 March, will… Read More

Webinar date:
Supported by Evotec
#News

#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Webinar: Advanced LC-MS bioanalytical strategies for biologics

A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar, taking place on 27 March, will… Read More

Webinar date:
Supported by Evotec
#News

#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Advanced LC-MS bioanalytical strategies for biologics: mAbs, ADCs, and oligonucleotides in complex biological matrices

This event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar will feature a presentation by Dr Marco… Read More

Webinar date:
Supported by Evotec
#Webinars

Antibody drug conjugate
#Antibody drug conjugate (ADC) #China #Kelun-Biotech #NMPA #Oncology #Solid tumours

Kelun-Biotech’s ADC IND for solid tumours approved in China

Kelun-Biotech’s Investigational New Drug (IND) application for SKB105 (CR-003), an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of advanced solid tumours.  In December 2025, Kelun-Biotech and Crescent Biopharma entered… Read More

#News #Regulatory

#Antibody drug conjugate (ADC) #Head and neck cancer #Oncology #Phase I trial #Pyxis Oncology

First-in-concept ADC shows promise in head and neck cancer

Pyxis Oncology has announced positive preliminary data from its ongoing Phase I clinical studies evaluating micvotabart pelidotin (MICVO) in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).   MICVO is an antibody-drug conjugate (ADC) targeting extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the… Read More

#Cancer Research #News